September 27, 2024

Community-Academic Partnership May Successfully Reduce Radon-Related Lung Cancer Risk in Native Population

A community and academic partnership may provide effective education about the risks of radon, testing for radon levels in the home, and reducing the risk of developing lung cancer among Native commun...

The ASCO Post

September 27, 2024

Datopotamab Deruxtecan vs Docetaxel in Previously Treated Advanced or Metastatic NSCLC

As reported in the Journal of Clinical Oncology by Ahn et al, the phase III TROPION-Lung01 trial showed significantly improved progression-free survival—but not overall survival—with datopotamab derux...

The ASCO Post

September 26, 2024

FDA Approves Osimertinib in Stage III NSCLC After Chemoradiotherapy

The U.S. Food and Drug Administration approved osimertinib (Tagrisso) for adults with locally advanced, unresectable (stage III) non–small cell lung cancer (NSCLC) whose disease has not progressed dur...

The ASCO Post

September 26, 2024

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

In the phase III HARMONi-2 study conducted in China, presented at the IASLC 2024 World Conference on Lung Cancer, the bispecific antibody ivonescimab was compared with the PD-1 inhibitor pembrolizumab...

The ASCO Post

September 25, 2024

Cancer Rates Recover, Rebound Eludes 2021 Data

Cancer rates returned to near prepandemic levels in 2021, however, distant-stage breast cancer incidence surpassed expectations, signaling potential COVID-19 screening disruption effects.

Conexiant

September 13, 2024

Taletrectinib in ROS1-Positive NSCLC: Focus on Prior Tyrosine Kinase Inhibitor Exposure Status

Researchers reported updated data from the global, multicenter, single-arm phase II TRUST-II trial with the next-generation ROS1 tyrosine kinase inhibitor taletrectinib in patients with locally advanc...

The ASCO Post

September 13, 2024

Using TROP2 Expression to Predict Outcomes in Advanced NSCLC

Researchers have uncovered that TROP2 expression as measured by quantitative continuous scoring may be a predictor of clinical outcomes in patients with advanced or metastatic non–small cell lung canc...

The ASCO Post

September 13, 2024

NeoCOAST-2 Trial: Durvalumab Plus Novel Agents May Increase Pathologic Responses in Resectable NSCLC

Researchers have demonstrated that the combination of durvalumab and the TROP2-directed antibody-drug conjugate datopotamab deruxtecan may yield high pathologic complete response rates in patients wit...

The ASCO Post

September 12, 2024

Study Compares Lung Cancer Screening Triage Protocols

The PanCan nodule management protocol was compared with the LungRADSv1.1 approach to determine which strategy was superior at triaging lung cancer screening participants, according to findings present...

The ASCO Post